1. Chan AYL, Yuen ASC, Tsai DHT, et al. Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study. Nat Commun. 2023;14(1):5005. doi:10.1038/s41467-023-40637-8
2. Gulec G, Kosger F, Essizoglu A. Alcohol and substance use disorders in DSM-5. Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry. Published online 2015. doi:10.5455/cap.20150325081809
3. Maldonado R, Calvé P, García-Blanco A, Domingo-Rodriguez L, Senabre E, Martín-García E. Vulnerability to addiction. Neuropharmacology. 2021;186:108466. doi:10.1016/j.neuropharm.2021.108466
4. Reed B, Kreek MJ. Genetic vulnerability to opioid addiction. Cold Spring Harb Perspect Med. 2021;11(6):a039735. doi:10.1101/cshperspect.a039735
5. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403-426. doi:10.1007/s40265-017-0700-x
6. Athavale A, Murnion B. Gabapentinoids: a therapeutic review. Aust Prescr. 2023;46(4):80-85. doi:10.18773/austprescr.2023.025
7. Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104-114. doi:10.1177/2049463720912496
8. McAnally H, Bonnet U, Kaye AD. Gabapentinoid benefit and risk stratification: mechanisms over myth. Pain Ther. 2020;9(2):441-452. doi:10.1007/s40122-020-00189-x
9. Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28(6):491-496. doi:10.1007/s40263-014-0164-4
10. Althobaiti YS, Almalki A, Alsaab H, et al. Pregabalin: potential for addiction and a possible glutamatergic mechanism. Sci Rep. 2019;9(1): 15136. doi:10.1038/s41598-019-51556-4
11. Stannard C. Misuse of gabapentin and pregabalin: a marker for a more serious malaise? Addiction (Abingdon, England). 2016;111(10):1699-1700. doi:10.1111/add.13408
12. Schjerning O, Rosenzweig M, Pottegård A, Damkier P, Nielsen J. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016;30(1):9-25. doi:10.1007/s40263-015-0303-6
13. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27(12):1185-1215. doi:10.1016/j.euroneuro.2017.08.430
14. Darke S, Duflou J, Peacock A, Farrell M, Lappin J. Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000-2020. Clin Toxicol. 2022;60(3):304-310. doi:10.1080/15563650.2021.1965159
15. Erden Y, Kaya SS, Okçu M. Pregabalin and gabapentin use disorders. Fiziksel Tıp ve Rehabilitasyon Bilimleri Dergisi. 2019;22(3):126-133. doi: 10.31609/jpmrs.2019-66052
16. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. Ann Pharmacother. 2016;50(3):229-233. doi:10.1177/ 1060028015620800
17. Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M. Gabapentinoid abuse in France: evidence on health consequences and new points of vigilance. Front Psychiatry. 2021;12:639780. doi:10. 3389/fpsyt.2021.639780
18. Grosshans M, Lemenager T, Vollmert C, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69(12):2021-2025. doi:10.1007/s00228-013-1578-5
19. Antunovic M, Vucinic S, Kotur-Stevuljevic J, et al. Rise of pregabalin poisoning and abuse cases in Serbia: a ten-year retrospective study. Int J Gen Med. 2023;16:1239-1250. doi:10.2147/IJGM.S405616
20. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the opioid risk tool. Pain Med. 2005;6(6):432-442. doi:10.1111/j.1526-4637.2005.00072.x
21. Warlick H, Leon L, Patel R, et al. Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model. Mol Biol Rep. 2023;50(2):1765-1784. doi:10.1007/s11033-022-08110-9
22. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind, placebo-controlled trial. J Psychopharmacol. 2012;26(4):461-470. doi:10.1177/0269881111405360
23. Wills B, Reynolds P, Chu E, et al. Clinical outcomes in newer anticonvulsant overdose: a poison center observational study. J Med Toxicol. 2014;10(3):254-260. doi:10.1007/s13181-014-0384-5
24. Novotny M, Bulla J, Hubl D, et al. Pregabalin use in forensic hospitals and prisons in German speaking countries—a survey study of physicians. Front Public Health. 2024;11:1309654. doi:10.3389/fpubh.2023.1309654
25. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10): e1002396. doi:10.1371/journal.pmed.1002396
26. Powell D, Shetty KD, Peet ED. Trends in overdose deaths involving gabapentinoids and Z-drugs in the United States. Drug Alcohol Depend. 2023;249:109952. doi:10.1016/j.drugalcdep.2023.109952
27. Kuo YF, Polychronopoulou E, Raji MA. Signal detection of adverse events associated with gabapentinoid use for chronic pain. Pharmacoepidemiol Drug Saf. 2024;33(1):e5685. doi:10.1002/pds.5685